Publications by authors named "Dhanushka H Bostanthirige"
Article Synopsis
- Dysregulated pre-mRNA splicing and metabolism are key features of cancers driven by the MYC oncogene, and targeting these processes has potential for cancer therapy.
- The study identifies JMJD6 as a central protein linking splicing and metabolism in MYC-driven neuroblastoma by interacting with RNA binding proteins and regulating specific glutaminase isoforms.
- Additionally, JMJD6's role in the cancer cell response to the drug indisulam suggests it might be a promising target for developing treatments for MYC-driven cancers.
Article Synopsis
- Dysregulated pre-mRNA splicing and metabolism are key characteristics of MYC-driven cancers, with JMJD6 identified as a critical link between these processes in MYC-driven neuroblastoma.
- JMJD6 collaborates with MYC and RNA binding proteins to regulate the alternative splicing of glutaminase isoforms, which are essential for cancer cell metabolism.
- The study suggests targeting JMJD6 may be a promising therapeutic strategy for treating MYC-driven cancers, especially in conjunction with drugs like indisulam that hinder splicing factors affecting JMJD6.
ID4 promotes AR expression and blocks tumorigenicity of PC3 prostate cancer cells.
Biochem Biophys Res Commun
September 2016
Deregulation of tumor suppressor genes is associated with tumorigenesis and the development of cancer. In prostate cancer, ID4 is epigenetically silenced and acts as a tumor suppressor. In normal prostate epithelial cells, ID4 collaborates with androgen receptor (AR) and p53 to exert its tumor suppressor activity.
View Article and Find Full Text PDF